We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02914639
First Posted: September 26, 2016
Last Update Posted: July 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
SciFluor Life Sciences, Inc.
  Purpose
The primary purpose of this study is to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).

Condition Intervention Phase
Age-Related Macular Degeneration Drug: SF0166 Topical Ophthalmic Solution Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-related Macular Degeneration (AMD)

Resource links provided by NLM:


Further study details as provided by SciFluor Life Sciences, Inc.:

Primary Outcome Measures:
  • Safety: Best-corrected Visual Acuity (BCVA) Change from Day 0 to Day 56 [ Time Frame: Assessed at Days 0, 14, 28, 42, and 56 ]
    Assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) method. Descriptive presentation of number of subjects with clinically significant changes from Baseline (Day 0) through Day 56 in BCVA.

  • Safety: Slit-lamp Findings Change from Day 0 to Day 56 [ Time Frame: Assessed at Days 0, 14, 28, 42, and 56 ]
    Areas to be assessed include conjunctiva, cornea, anterior chamber, and lens; determination of normal or abnormal made by Investigators. Descriptive presentation of number of subjects with clinically significant changes from Baseline (Day 0) through Day 56 in abnormal slit-lamp findings.

  • Safety: Fundus Findings Change from Day 0 to Day 56 [ Time Frame: Assessed at Days 0, 14, 28, 42, and 56 ]
    Areas to be assessed include vitreous, fundus, optic nerve, cup to disc ratio, macula and choroid, vessels and peripheral retina; determination of normal or abnormal made by Investigators. Descriptive presentation of number of subjects with clinically significant changes from Baseline (Day 0) through Day 56 in abnormal fundus findings.

  • Safety: Intraocular Pressure (IOP) Change from Day 0 to Day 56 [ Time Frame: Assessed at Days 0, 14, 28, 42, and 56 ]
    Measured in millimeters of mercury (mmHg) by Tonopen or Applanation. Descriptive presentation of number of subjects with clinically significant changes from Baseline (Day 0) through Day 56 in IOP.

  • Safety: Adverse Events (AEs) Change from Day 0 to Day 56 [ Time Frame: Assessed at Days 0, 14, 28, 42, and 56 ]
    Ocular and non-ocular events collected and summarized descriptively; presentation of number of subjects with reported adverse events or serious adverse events.


Secondary Outcome Measures:
  • Primary Efficacy: Mean Change in Anatomic Center Subfield Thickness from Day 0 to Days 14, 28, 42, and 56 [ Time Frame: Days 0, 14, 28, 42, and 56 ]
    Measured in microns (μm) by optical coherence tomography (OCT). Descriptive presentation at each study visit time point; no hypothesis testing.

  • Primary Efficacy: Mean Change in Macular Volume from Day 0 to Days 14, 28, 42, and 56 [ Time Frame: Days 0, 14, 28, 42, and 56 ]
    Measured in cubic millimeters (mm3) by optical coherence tomography (OCT). Descriptive presentation at each study visit time point; no hypothesis testing.

  • Secondary Efficacy: Mean Change in Best-corrected Visual Acuity (BCVA) from Day 0 to Days 14, 28, 42, and 56 [ Time Frame: Days 0, 14, 28, 42, and 56 ]
    Assessed with Early Treatment Diabetic Retinopathy Study (ETDRS) method. Descriptive presentation at each study visit time point; no hypothesis testing.


Enrollment: 44
Actual Study Start Date: October 5, 2016
Study Completion Date: June 26, 2017
Primary Completion Date: June 26, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SF0166 low dose BID
SF0166 low dose will be instilled in study eye BID for 28 days of treatment.
Drug: SF0166 Topical Ophthalmic Solution
Experimental: SF0166 high dose BID
SF0166 high dose will be instilled in study eye BID for 28 days of treatment.
Drug: SF0166 Topical Ophthalmic Solution

Detailed Description:

This is a prospective, randomized, double-masked, multicenter, Phase I/II clinical study in which up to 40 eligible subjects with Neovascular Age-related Macular Degeneration (AMD)will be randomized to 1 of 2 treatment arms in a 1:1 ratio as follows: SF0166 low dose twice daily (BID) or SF0166 high dose BID.

The study population includes male and female subjects, aged 50 or older, with active subfoveal choroidal neovascularization due to Age-related Macular Degeneration (AMD) that meet the following criteria: ≤12 Macular Photocoagulation Study [MPS] disc areas, with choroidal neovascularization [CNV] >50% of the total lesion area), retinal or subretinal fluid visible on optical coherence tomography (OCT), and no treatment with anti-vascular endothelial growth factor (VEGF) therapy in the study eye within up to 60 days of study entry.

If a subject qualifies in both eyes, SF0166 may be administered to both eyes (study eye and non-study eye) at the discretion of the Investigator.

Study subjects will administer the randomly assigned treatment for 28 days. There is an additional 28-day post-treatment follow-up period. All study subjects will return for examination every 2 weeks for 8 weeks (2 months).

All outcomes and assessments will be summarized descriptively for Days 0, 14, 28, 42, and 56. No formal hypotheses will be tested.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 50 years of age or older.
  2. Active subfoveal choroidal neovascularization due to Age-related Macular Degeneration (AMD) in the study eye that meet the following criteria:

    • Total lesion ≤12 Macular Photocoagulation Study (MPS) disc areas
    • Choroidal neovascularization (CNV) >50% of lesion area
    • Intraretinal or subretinal fluid due to choroidal neovascularization (CNV) visible on optical coherence tomography (OCT)
    • No atrophy or fibrosis involving the center of the fovea
  3. Best-corrected Visual Acuity (BCVA) between 78 and 25 letters, inclusive, in the study eye at the screening/randomization visit using Early Treatment Diabetic Retinopathy Study (ETDRS) testing, with BCVA decrement primarily attributable to neovascular Age-related Macular Degeneration (AMD).
  4. Treatment naïve (i.e., no previous anti--vascular endothelial growth factor [VEGF] treatment in the study eye) or previously treated study eye with adequate washout defined below:

    1. Lucentis (ranibizumab): 30-day washout
    2. Avastin (bevacizumab): 30-day washout
    3. Eylea (aflibercept): 60-day washout
    4. Macugen (pegaptanib): 45-day washout
  5. Willing and able to return for all study visits.
  6. Able to adhere to the study dosing requirements.
  7. Understands and signs the written informed consent form.

Exclusion Criteria:

  1. Non-study eye best corrected visual acuity (BCVA) worse than 20 letters at the screening/randomization visit using Early Treatment Diabetic Retinopathy Study (ETDRS) testing.
  2. Choroidal neovascularization (CNV) in the study eye secondary to other causes (e.g., pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, posterior uveitis, or multifocal choroiditis).
  3. Previous macular laser photocoagulation or ocular photodynamic therapy in the study eye.
  4. Media opacities or abnormalities in the study eye that would preclude visualization of the retina.
  5. Other retinal pathologies in the study eye that would interfere with vision.
  6. Retinal pigment epithelial (RPE) tear in the study eye.
  7. Significant epiretinal membrane, posterior hyaloidal traction, and/or vitreomacular traction in the study eye as determined by optical coherence tomography (OCT) results.
  8. Uncontrolled glaucoma or ocular hypertension in the study eye defined as an Intraocular Pressure (IOP) >25 millimeter of mercury (mmHg) regardless of concomitant treatment with IOP lowering medications.
  9. Uncontrolled hypertension defined as systolic >180 mmHg or >160 mmHg on 2 consecutive measurements (during the same visit) or diastolic >100 mmHg on optimal medical regimen
  10. Previous pars plana vitrectomy in the study eye.
  11. Any intraocular surgery in the study eye within 90 days (3 months) prior to study enrollment.
  12. Yttrium aluminium garnet (YAG) laser treatment in the study eye within 30 days (1 month) prior to study enrollment.
  13. Intravitreal/periocular/topical ocular steroids of any type in the study eye within 90 days (3 months) prior to study enrollment.
  14. Concomitant use any topical ophthalmic medications in the study eye, including dry eye or glaucoma medications, unless on a stable dose for at least 90 days (3 months) prior to study enrollment and expected to stay on stable dose throughout study participation. Artificial tears are allowed.
  15. Chronic or recurrent uveitis in the study eye.
  16. Ongoing ocular infection or inflammation in either eye.
  17. A history of cataract surgery complicated by vitreous loss in the study eye.
  18. Congenital eye malformations in the study eye.
  19. A history of penetrating ocular trauma in the study eye.
  20. Mentally handicapped.
  21. Females of childbearing potential (i.e., who are not postmenopausal for at least 1 year or surgically sterile for at least 6 weeks prior to Visit 1 - Screening/Randomization) who are lactating, or who are pregnant as determined by a positive urine pregnancy test (UPT) at Visit 1 - Screening/Randomization. Women of childbearing potential must agree to use acceptable methods of birth control throughout the study. Acceptable methods of birth control include tubal ligation, transdermal patch, intrauterine devices/systems, oral/implantable/injectable or contraceptives, sexual abstinence, double barrier method, or vasectomized partner.
  22. Participation in any other investigational device or drug clinical research study within 30 days of Visit 1 - Screening/Randomization.
  23. Contraindication to the study medications or fluorescein dye.
  24. Other ocular pathologies that in the Investigator's opinion would interfere with vision in the study eye.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02914639


Locations
United States, Arizona
Retinal Research Institute LLC
Phoenix, Arizona, United States, 85014
United States, California
Retina Consultants of Orange County
Fullerton, California, United States, 92861
Northern California Retina Vitreous Associates Medical Group, Inc
Mountain View, California, United States, 94040
United States, Florida
Retina Macula Specialists of Miami, LLC
Miami, Florida, United States, 33126
Center for Retina and Macular Disease
Winter Haven, Florida, United States, 33880
United States, Indiana
John Kenyon Eye Institute
New Albany, Indiana, United States, 47150
United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
United States, South Dakota
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States, 57701
United States, Texas
West Texas Retina Consultants
Abilene, Texas, United States, 79606
Retina Research Center, PLLC
Austin, Texas, United States, 78705
Texas Retina Associates
Fort Worth, Texas, United States, 76104
United States, Washington
Spokane Eye Clinical Research
Spokane, Washington, United States, 99204
Sponsors and Collaborators
SciFluor Life Sciences, Inc.
Investigators
Study Chair: Gary Foulks, MD Medical Monitor
  More Information

Responsible Party: SciFluor Life Sciences, Inc.
ClinicalTrials.gov Identifier: NCT02914639     History of Changes
Other Study ID Numbers: SF0166-C-002
First Submitted: September 1, 2016
First Posted: September 26, 2016
Last Update Posted: July 21, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Pharmaceutical Solutions
Ophthalmic Solutions